First patient enrolled in Phase 3 trial of mocertatug rezetecan for platinum-resistant ovarian cancer
Philadelphia, PA, USA — July 27, 2026 — The GOG Foundation, Inc. announced the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 trial evaluating mocertatug rezetecan against standard-of-care...
Read moreDetails
